Multidrug-resistant infections in war victims in Ukraine.

Competing Interests: LSPM has consulted for bioMerieux (2013–23), Eumedica (2016–22) and Pfizer (2018–22); received speaker fees from Kent Pharma (2021), Pulmocide (2021), Uvomis Lab (2020), Sumiovant (2021–22), Phenutest (2023), and Shionogi (2021–22); and received research grants from the National Institute for Health Research (2013–20), CW+ (2018–22), Infectiopharm (2022–23), and LifeArc (2020–22). AT has received royalties from JP Medical and Oxford University Press; consulted for Stryker, Meshworks, and Orthofix; and received speaker fees from Stryker, Meshworks, Orthofix, and Smith+Nephew. SEB has consulted for bioMerieux and Sumitovant, received speaker fees from Shionogi and the UK Clinical Pharmacy Association, and was supported by a research grant obtained through a Medical Research Council (MRC)-awarded UK Research and Innovation Fellowship within the North West England MRC Scheme in Clinical Pharmacology with support from Roche Pharma (2017–21). SJCP has received a research grant from the Scientific Exploration Society. MB declares no competing interests. LSPM acknowledges support from the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre and the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London, London, UK in partnership with the UK Health Security Agency. We acknowledge support from South West London Pathology for culture and susceptibility testing of isolated organisms. Written informed consent was provided by the patient for submission of this case for publication.